Your browser is no longer supported. Please, upgrade your browser.
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-14.82 Insider Own0.30% Shs Outstand74.75M Perf Week14.09%
Market Cap16.37B Forward P/E7.96 EPS next Y27.40 Insider Trans-63.80% Shs Float- Perf Month53.99%
Income-1075.00M PEG- EPS next Q5.96 Inst Own50.20% Short Float- Perf Quarter-3.84%
Sales1.20B P/S13.60 EPS this Y-32.00% Inst Trans-5.91% Short Ratio1.69 Perf Half Y47.66%
Book/sh6.17 P/B35.33 EPS next Y416.40% ROA-45.20% Target Price260.60 Perf Year112.45%
Cash/sh25.79 P/C8.45 EPS next 5Y0.00% ROE-149.70% 52W Range94.67 - 331.68 Perf YTD95.47%
Dividend- P/FCF36.08 EPS past 5Y9.50% ROI-38.00% 52W High-34.28% Beta1.34
Dividend %- Quick Ratio1.20 Sales past 5Y67.30% Gross Margin- 52W Low130.24% ATR14.58
Employees791 Current Ratio1.20 Sales Q/Q13.90% Oper. Margin-86.80% RSI (14)66.63 Volatility6.09% 7.32%
OptionableYes Debt/Eq0.93 EPS Q/Q-34.60% Profit Margin-89.30% Rel Volume1.26 Prev Close200.07
ShortableYes LT Debt/Eq0.70 EarningsNov 04 AMC Payout- Avg Volume4.89M Price217.97
Recom2.20 SMA2022.25% SMA5020.04% SMA20010.17% Volume6,145,777 Change8.95%
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Nov-28-21 06:59PM  
02:38PM  
11:45AM  
10:30AM  
Nov-27-21 10:15PM  
07:22PM  
01:30PM  
09:03AM  
Nov-26-21 10:50PM  
06:04PM  
02:41PM  
01:44PM  
01:32PM  
12:00PM  
11:40AM  
11:00AM  
10:53AM  
10:40AM  
10:25AM  
10:03AM  
09:42AM  
09:30AM  
09:27AM  
09:17AM  
05:35AM  
Nov-25-21 11:42PM  
11:10PM  
07:00PM  
08:50AM  
07:35AM  
Nov-24-21 11:33PM  
05:07PM  
04:55PM  
02:37PM  
12:27PM  
11:17AM  
11:00AM  
08:30AM  
07:00AM  
06:25AM  
12:04AM  
Nov-23-21 06:16PM  
04:30PM  
01:12PM  
12:00PM  
11:55AM  
11:50AM  
10:26AM  
09:15AM  
Nov-22-21 10:39PM  
10:30PM  
06:19PM  
04:20PM  
04:00PM  
03:45PM  
02:46PM  
02:29PM  
02:10PM  
01:30PM  
01:29PM  
11:30AM  
11:15AM  
11:00AM  
10:21AM  
09:41AM  
08:50AM  
05:28AM  
Nov-21-21 10:45PM  
06:15PM  
06:30AM  
Nov-20-21 09:36PM  
06:13PM  
Nov-19-21 10:00PM  
09:44PM  
06:00PM  
02:59PM  
02:53PM  
01:30PM  
01:15PM  
12:29PM  
11:00AM  
10:45AM  
10:30AM  
10:00AM  
09:30AM  
05:40AM  
Nov-18-21 11:26PM  
10:05PM  
07:58PM  
06:28PM  
05:40PM  
05:25PM  
04:45PM  
03:40PM  
03:16PM  
02:41PM  
02:26PM  
01:56PM  
12:58PM  
12:20PM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Gregory MPresident, R&DNov 23Option Exercise19.088,250157,41012,311Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 23Sale199.508,2501,645,9144,061Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 16Option Exercise19.088,250157,41012,311Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 16Sale169.488,2501,398,1804,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Option Exercise37.901,18344,8325,244Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Sale172.021,183203,4964,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 09Option Exercise19.088,250157,41012,311Nov 12 05:02 PM
Glenn Gregory MPresident, R&DNov 09Sale167.538,2501,382,1604,061Nov 12 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Option Exercise19.085,00095,4007,760Nov 05 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Sale200.005,0001,000,0002,760Nov 05 05:02 PM
Glenn Gregory MPresident, R&DNov 02Option Exercise19.088,250157,41012,311Nov 04 05:22 PM
Glenn Gregory MPresident, R&DNov 02Sale183.828,2501,516,5524,061Nov 04 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Option Exercise19.085,00095,4007,760Nov 03 04:49 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Sale163.085,000815,4222,760Nov 03 04:49 PM
Glenn Gregory MPresident, R&DOct 29Sale148.34680100,8714,061Nov 02 07:02 PM
Glenn Gregory MPresident, R&DOct 26Option Exercise15.2011,712178,00914,395Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 26Sale132.7310,3341,371,6674,061Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 19Option Exercise19.088,250157,41012,311Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 19Sale165.148,2501,362,4274,061Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 15Option Exercise37.901,18344,8325,244Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 15Sale170.001,183201,1104,061Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 12Option Exercise19.088,250157,41012,311Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 12Sale163.188,2501,346,2184,061Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 05Option Exercise19.088,250157,41012,311Oct 07 05:18 PM
Glenn Gregory MPresident, R&DOct 05Sale174.418,2501,438,8954,061Oct 07 05:18 PM
Erck Stanley CPresident and CEOOct 04Option Exercise27.4542,8291,175,58366,708Oct 05 05:05 PM
Erck Stanley CPresident and CEOOct 04Sale176.1542,8297,544,19523,879Oct 05 05:05 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Option Exercise19.085,00095,4007,760Oct 05 05:02 PM
Erck Stanley CPresident and CEOOct 01Option Exercise27.1749,0001,331,40072,879Oct 05 05:04 PM
Erck Stanley CPresident and CEOOct 01Sale175.1049,0008,580,06423,879Oct 05 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Sale174.895,000874,4522,760Oct 05 05:02 PM
Glenn Gregory MPresident, R&DSep 30Sale207.25693143,6224,061Oct 01 05:58 PM
Trizzino JohnEVP, CCO and CBOSep 28Option Exercise19.087,501143,11910,047Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 28Sale209.927,5011,574,6372,546Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 27Option Exercise19.087,501143,11910,047Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Option Exercise5.953,46020,5876,144Sep 29 05:08 PM
Glenn Gregory MPresident, R&DSep 27Sale234.432,083488,3154,061Sep 29 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 27Sale234.617,5011,759,8332,546Sep 29 05:04 PM
MOTT DAVID MDirectorSep 23Sale252.9024,9616,312,61640,000Sep 24 05:10 PM
Trizzino JohnEVP, CCO and CBOSep 21Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 21Sale227.377,5001,705,265718Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Sale227.577,5001,706,748718Sep 22 05:05 PM
Glenn Gregory MPresident, R&DSep 15Option Exercise37.901,18344,8325,244Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Option Exercise19.085,00095,4005,706Sep 17 05:11 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Sale229.445,0001,147,193706Sep 17 05:11 PM
Glenn Gregory MPresident, R&DSep 15Sale229.341,183271,3044,061Sep 17 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 14Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 14Sale236.617,4991,774,360718Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Sale235.297,4991,764,433718Sep 15 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Option Exercise19.085,00095,4005,706Sep 03 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Sale247.975,0001,239,867706Sep 03 05:10 PM
Glenn Gregory MPresident, R&DAug 31Sale239.871,386332,4634,061Sep 01 05:23 PM
Glenn Gregory MPresident, R&DAug 26Option Exercise5.956,92141,1808,228Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 26Sale233.924,167974,7404,061Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 16Option Exercise40.641,86675,8265,927Aug 18 05:26 PM
Glenn Gregory MPresident, R&DAug 16Sale233.521,866435,7504,061Aug 18 05:26 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Option Exercise14.832,89642,9603,602Jul 28 05:00 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Sale197.742,896572,648706Jul 28 05:00 PM
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Sale239.832,895694,317275May 04 06:03 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM